A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis

Abstract

Gastrointestinal stromal tumor (GIST) is the most common sarcoma arising in the gastrointestinal (GI) tract. Imatinib mesylate (imatinib) is efficacious in treating advanced and metastatic GIST. Patients undergoing resection of GIST realize a highly variable median disease-free survival (DFS). In the absence of prospective data, we conducted a randomized, phase II study to assess the safety and efficacy of preoperative and postoperative imatinib for the treatment of GIST. Nineteen GIST patients undergoing surgical resection were randomized to receive 3, 5, or 7 days of preoperative imatinib (600 mg daily). Patients received postoperative imatinib for 2 years. Perioperative adverse events were compared with those in an imatinib-naïve historical control. The efficacy of imatinib was assessed by (18)fluorodeoxyglucose positron emission tomography ((18)FDG-PET), dynamic computed tomography (dCT), terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, and DFS. Imatinib did not affect surgical morbidity as compared with an imatinib-naïve cohort (p >/= 0.1). Most patients responded to preoperative imatinib by (18)FDG-PET and dCT (69% and 71%, respectively). Tumor cell apoptosis increased by an average of 12% (range 0-33%) and correlated with the duration of preoperative imatinib (p = 0.04). Median DFS of patients treated with surgery and imatinib was 46 months (range 10-46 months). Tumor size was a predictor of recurrence after postoperative imatinib (p = 0.02). Imatinib appears to be safe and may be considered for patients undergoing surgical resection of their GIST. Radiographic response and tumor cell apoptosis occur within the first week of imatinib therapy.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 30

1. 1.

   Steinert DM, McAuliffe JC, Trent JC. Imatinib mesylate in the treatment of gastrointestinal stromal tumour. Expert Opin Pharmacother. 2005;6:105-13.

   Not in our library10.1517/14656566.6.1.105

2. 2.

   Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259-69.

   Not in our library

3. 3.

   Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-80.

   Not in our library10.1126/science.279.5350.577

4. 4.

   Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-10.

   Not in our library10.1126/science.1079666

5. 5.

   Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002;1:493-502.

   Not in our library10.1038/nrd839

6. 6.

   Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127-34.

   Not in our library10.1016/s0140-6736(04)17098-0

7. 7.

   Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626-32.

   Not in our library10.1200/jco.2007.13.4452

8. 8.

   DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51-8.

   Not in our library10.1097/00000658-200001000-00008

9. 9.

   Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer. 2002;38:S37-8.

   Not in our library10.1016/s0959-8049(02)80601-3

10. 10.

    Blanke CD, Eisenberg BL, Heinrich MC. Gastrointestinal stromal tumors. Curr Treat Options Oncol. 2001;2:485-91.

    Not in our library10.1007/s11864-001-0070-0

11. 11.

    Pawlik TM, Vauthey JN, Abdalla EK, et al. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg. 2006;141:537-43.

    Not in our library10.1001/archsurg.141.6.537

12. 12.

    Ng EH, Pollock RE, Romsdahl MM. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer. 1992;69:1334-41.

    Not in our library10.1002/1097-0142(19920315)69:6<1334::aid-cncr2820690606>3.0.co;2-s

13. 13.

    DCTD, NCI, NIG, DHHS. Common Terminology Criteria For Adverse Events. Cancer Therapy Evaluation Program. 2003.

    Not in our library

14. 14.

    Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. 2002;20:3898-905.

    Not in our library10.1200/jco.2002.03.095

15. 15.

    Trent JC, Ramdas L, Dupart J, et al. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. Cancer. 2006;107:1898-908.

    Not in our library10.1002/cncr.22214

16. 16.

    Therneau T, Grambsch P. Modeling survival data. 2000.

    Not in our library

17. 17.

    Kaplan E, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958;53:457-81.

    Not in our library

18. 18.

    Snedecor G, Cochran W. Statistical methods. 1980.

    Not in our library

19. 19.

    Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-80.

    Not in our library10.1056/nejmoa020461

20. 20.

    Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42:1093-103.

    Not in our library10.1016/j.ejca.2006.01.030

21. 21.

    Bidri M, Ktorza S, Vouldoukis I, et al. Nitric oxide pathway is induced by Fc epsilon RI and up-regulated by stem cell factor in mouse mast cells. Eur J Immunol. 1997;27:2907-13.

    Not in our library10.1002/eji.1830271124

22. 22.

    Van Buren G, Camp ER, Yang AD, et al. The role of nitric oxide in mediating tumour blood flow. Expert Opin Ther Targets. 2006;10:689-701.

    Not in our library10.1517/14728222.10.5.689

23. 23.

    McAuliffe JLA, Steinert D, Patel S, Benjamin R, Trent J. Kitstem cell factor (Kit ligand) axis in GIST patients treated with imatinib. 2007.

    Not in our library

24. 24.

    Sihto H, Tynninen O, Bèutzow R, et al. Endothelial cell KIT expression in human tumours. J Pathol. 2007;211:481-8.

    Not in our library10.1002/path.2125

25. 25.

    Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;111:1287-95.

    Not in our library10.1172/jci17929

26. 26.

    Dematteo ROK, Maki R, Pisters P, Blackstein M, Antonescu C, Blanke C, et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrintestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. 2007.

    Not in our library

27. 27.

    Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol. 2007;14:14-24.

    Not in our library10.1245/s10434-006-9034-8

28. 28.

    Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multi-centric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007;25:1107-13.

    Not in our library10.1200/jco.2006.09.0183

29. 29.

    Eisenberg BL. Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trials. Clin Colorect Cancer. 2006;6:S24-9.

    Not in our library10.3816/ccc.2006.s.004

30. 30.

    Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052-6.

    Not in our library10.1056/nejm200104053441404

Cited by papers we hold 1

• BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance · 2013
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.